Nerve Fresh Reviews (URGENT REPORT) Consumer Complaints, Ingredients & What Doctors Reveal About Side Effects in 2025 
Counterpart Health Expands Proven Flywheel for HEDIS Excellence to Third-Party Partners
Technology platform again powers top-tier HEDIS results for Clover Health Medicare Advantage plansSAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) --...
2026 Top Health Information Management Systems Vendors
Independent Black Book user experience rankings spotlight vendors leading the modernization of health information management from AI-powered coding to interoperable...
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced...
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer...
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track...
Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It
BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) didn't tiptoe into reinvention. It jumped....
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft ModelsFLORHAM...
CLn Skin Care Appoints Dr. Amir Moradi to Medical Advisory Board
Acclaimed Facial Plastic Surgeon and Educator Joins CLn Skin Care DALLAS, TEXAS / ACCESS Newswire / October 14, 2025 /...
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
As “Uptober” Ignites Crypto Market, Bonk, Inc. Revs Up Its Revenue-Generating Engine
Company to Capitalize on its Position as the Most Widely Held Token on Solana and a Historically Strong Q4 for...
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...
FibroBiologics to Present at the 2025 ThinkEquity Conference
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued...
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
CBD Life Sciences Inc. (CBDL) Lands Major Order from Bronx Dispensary “Smoking Scholars,” Signaling Explosive Growth Ahead for CBD-Infused Drinks Division
Strong consumer demand and rapid market adoption drive CBDL's beverage expansion as top-selling CBD Lemonade, Raspberry Lemonade, and Lavender Lemonade...
Every Word Matters: The Next Chapter of Our Universal Patient Language
Originally published on BMS.com in recognition of Health Literacy Month, the following article highlights how Bristol Myers Squibb's Universal Patient...
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed...
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis...
Zomedica Expands Grovet’s Distribution Agreement to Include Zomedica’s Diagnostic and Therapeutic Device Products Across the European Union
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in...
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation...
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...